Clinical Trial Update: A Trial Of CVX-060, An Anti-Angiogenic COVX-Body, In Combination With Sunitinib In Patients With Advanced Renal Cell Carcinoma [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating CVX-060 in combination with sunitinib for advanced renal cell carcinoma was terminated; results were posted in 2015.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Renal Cell Carcinoma

Drugs mentioned

• CVX-060
• Sutent (sunitinib)

Snippet

Sponsor: Pfizer | Conditions: Solid Tumor | Phase 2 | Status: TERMINATED | Results posted: 2015-08-24